Raute’s Q4 margins were a bit lower than we estimated even if top line was higher than we expected.
Etteplan's Q4 results aligned with our estimates, with NRIs weighing on the figures.
Q4: EBITDA of NOK 5m vs ABGSCe NOK 6m Lower target range likely Estimates likely unchanged Q4: EBIT...
Adj. EBITA -11% vs ABG, -13% vs consensus Service companies drove the miss, products held up better ...
Redeye comments on a solid Q4 report in a soft market, showing that CombinedX is back among the qual...
Sales slightly above ABGSCe, ARR in line Limited consensus estimate revisions are likely Variable re...
Q4 sales -1% below our ests. at SEK 229m, for 12.5% org.
F&MT recovers from Q3 challenges Scandpower ends the year in style Decommissioning behind 5% cut to ...
Q4-rapporten kom in i med våra prognoser efter vinstvarningen.
Redeye notes a substantial sales contribution from distributors, in which Thermo Fisher sales are re...
Redeye is encouraged by the upbeat Q4 report showing solid top-line numbers and a small profit on EB...
Beijer Alma levererar ett kvartal med både organisk och förvärvdriven tillväxt trots en svagare indu...
Redeye comments on Fortnox’s Q4 report, showing underlying numbers largely matching our expectations...
Redeye comments on Nekkar’s Q4’24 report that beat our expectations mainly driven by higher activity...
ExpreS2ion Biotechnologies har påbörjat screening av deltagare i bolagets fas 1-studie med vaccinkan...
Redeye provides an initial take following the release of SenzaGen’s Q4 2024 report.
Redeye’s initial take on Stille’s year-end report is positive.
Redeye provides an initial take following the release of Optomed’s Q4 2024 report.
Redeye comments on Embracer’s Q3-results which were in line with the preannounced results.
Redeye comments on Thunderful Group’s Q4’24 report, which came in better than expected in terms of s...
